We identified a discrete number of microRNAs differentially expressed in benign or malignant mesothelial tissues. We focused on mir-145 whose levels were significantly downregulated in malignant mesothelial tissues and malignant pleural mesothelioma (MPM) cell lines as compared to benign tissues (pleura, peritoneum or cysts). We show that promoter hyper-methylation caused very low levels in MPM cell lines and specimens. Treatment of MPM cell lines with mir-145 agonists negatively modulated some protumorigenic properties of MPM cells, such as clonogenicity, cell migration and resistance to pemetrexed treatment. The main effector mechanism of the clonogenic death induced by mir-145 was that of accelerated senescence. We found that mir-145 targeted OCT4 via specific binding to its 30-UTR. Increased intracellular levels of mir-145 decreased the levels of OCT4 and its target gene ZEB1, thereby counteracting the increase of OCT4 induced by pemetrexed treatment which is known to favor the development of chemoresistant cells. In line with this, reintroduction of OCT4 into mimic-145 treated cells counteracted the effects on clonogenicity and replicative senescence. This further supports the relevance of the mir-145-OCT4 interaction for the survival of MPM cells. The potential use of mir-145 expression levels to classify benign vs malignant mesothelial tissues and the differences between pemetrexed-induced senescence and that induced by the re-expression of mir-145 are discussed.

Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma / M. Cioce, F. Ganci, V. Canu, A. Sacconi, F. Mori, C. Canino, E. Korita, B. Casini, G. Alessandrini, A. Cambria, M.A. Carosi, R. Blandino, V. Panebianco, F. Facciolo, P. Visca, S. Volinia, P. Muti, S. Strano, C.M. Croce, H.I. Pass, G. Blandino. - In: ONCOGENE. - ISSN 0950-9232. - 33:46(2014), pp. 5319-5331. [10.1038/onc.2013.476]

Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma

P. Muti
Conceptualization
;
2014

Abstract

We identified a discrete number of microRNAs differentially expressed in benign or malignant mesothelial tissues. We focused on mir-145 whose levels were significantly downregulated in malignant mesothelial tissues and malignant pleural mesothelioma (MPM) cell lines as compared to benign tissues (pleura, peritoneum or cysts). We show that promoter hyper-methylation caused very low levels in MPM cell lines and specimens. Treatment of MPM cell lines with mir-145 agonists negatively modulated some protumorigenic properties of MPM cells, such as clonogenicity, cell migration and resistance to pemetrexed treatment. The main effector mechanism of the clonogenic death induced by mir-145 was that of accelerated senescence. We found that mir-145 targeted OCT4 via specific binding to its 30-UTR. Increased intracellular levels of mir-145 decreased the levels of OCT4 and its target gene ZEB1, thereby counteracting the increase of OCT4 induced by pemetrexed treatment which is known to favor the development of chemoresistant cells. In line with this, reintroduction of OCT4 into mimic-145 treated cells counteracted the effects on clonogenicity and replicative senescence. This further supports the relevance of the mir-145-OCT4 interaction for the survival of MPM cells. The potential use of mir-145 expression levels to classify benign vs malignant mesothelial tissues and the differences between pemetrexed-induced senescence and that induced by the re-expression of mir-145 are discussed.
Chemoresistance; Mesothelial cysts; Mesothelioma; Mir-145; OCT4; Senescence; 3' Untranslated Regions; Animals; Antineoplastic Agents; Base Sequence; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Cellular Senescence; DNA Methylation; Down-Regulation; Gene Knockdown Techniques; Glutamates; Guanine; HEK293 Cells; Humans; Lung Neoplasms; Male; Mesothelioma; Mice, SCID; MicroRNAs; Octamer Transcription Factor-3; Pemetrexed; Pleural Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Nucleic Acid; Gene Expression Profiling; Gene Expression Regulation, Neoplastic
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
2014
Article (author)
File in questo prodotto:
File Dimensione Formato  
nihms742835.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 2.48 MB
Formato Adobe PDF
2.48 MB Adobe PDF Visualizza/Apri
onc2013476.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 4.15 MB
Formato Adobe PDF
4.15 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/662628
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 74
  • ???jsp.display-item.citation.isi??? 62
  • OpenAlex ND
social impact